Source comparison
GHRP-2 Acetate vs Tesamorelin + Ipamorelin Blend: Research Application Comparison
Receptor Selectivity Broad ghrelin receptor agonism (GHS-R1a); activates appetite, gastric, and reward pathways Dual-selective: GHRH receptor (tesamorelin) + selective ghrelin GH pathway (ipamorelin) Blend isolates GH pathway without confounding hunger or cort
This comparison does not assign a generated winner or score.
- Receptor Selectivity
- Broad ghrelin receptor agonism (GHS-R1a); activates appetite, gastric, and reward pathways
- Dual-selective: GHRH receptor (tesamorelin) + selective ghrelin GH pathway (ipamorelin)
- Blend isolates GH pathway without confounding hunger or cortisol signals. Critical for metabolic studies
- Cortisol/Prolactin Effect
- +40–60% cortisol, +25–35% prolactin per dose
- No detectable cortisol or prolactin elevation at standard research doses
- GHRP-2's stress hormone activation invalidates protocols studying fat loss or insulin sensitivity
- Half-Life & Dosing
- 20–30 min; requires 2–3× daily dosing
- Tesamorelin 38 min + ipamorelin 2 hr; once-daily dosing viable
- Extended half-life reduces injection frequency and eliminates cumulative cortisol exposure
- GH Release Pattern
- Sharp pulse (30–45 min peak, returns to baseline by 90 min)
- Biphasic: rapid onset + sustained 4–6 hr elevation
- Blend's extended AUC produces 2.5× greater total GH exposure per injection cycle
- Visceral Fat Reduction
- Indirect via GH lipolytic action; confounded by cortisol's lipogenic effect
- Tesamorelin specifically reduces VAT by 15–18% in HIV lipodystrophy trials (NEJM 2010)
- Tesamorelin has unique VAT-targeting evidence; GHRP-2 lacks this specificity
- Research Application Fit
- Acute GH signalling studies, receptor binding assays, short-term protocols (≤7 days)
- Body composition research, metabolic studies, neuroprotection models, multi-week protocols
- Use GHRP-2 for mechanism studies; use blend for outcome-driven research